Neuroligin 1—A New Substrate for γ-Secretase
These ideas will be discussed in the Alzforum Webinar.—Esther Landhuis None
373 RESULTS
You searched Esther AND Landhuis
Sort By:
These ideas will be discussed in the Alzforum Webinar.—Esther Landhuis None
Parkinson’s, AD or ALS.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=3291 Frontotemporal
Matta said.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=3286 Parkinson's Disease
venture capitalist.—Esther Landhuis. Q&A With Claude Wischik. Questions by Esther Landhuis. Q: The
compared to unaffected controls, suggesting it could serve as a disease biomarker, Abeliovich said.—Esther
a Phase 3 AD trial (see ARF related news story).—Esther Landhuis None
regulate dopaminergic loss in DJ-1-deficient mice will require further analysis,” the authors wrote.—Esther
fully effective against late-onset AD.”—Esther Landhuis None
assay.”—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=3259 Alzheimer's Disease Biomarkers
buildup.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=3244 Alzheimer's Disease Imaging
hypothesis,” Chapuis suggested in an e-mail to Alzforum.—Esther Landhuis. None
patients, Baker said.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=3237 Alzheimer's
Alzforum.—Esther Landhuis. None http://www.alzforum.org/new/detail.asp?id=3235 Alzheimer's Disease Amyloid
inhibitors. It’s just a note of caution as we move forward with these compounds in clinical trials.”—Esther
going to give us new handles on investigating the neuropathology of diseases like AD.”—Esther Landhuis